Effects of a novel <scp>GABA</scp>‐B positive allosteric modulator, <scp>ASP8062</scp>, on alcohol cue‐elicited craving and naturalistic alcohol consumption in a multisite randomized, double‐blind, placebo‐controlled trial
Although ASP8062 was well tolerated with no serious AEs, the novel compound did not significantly dampen alcohol cue-elicited craving or improve other AUD-related outcome measures. These data indicate positive allosteric modulation of the GABA<sub>B</sub> receptor at the dose evaluated here may not blunt alcohol cue-elicited craving, and preliminary drinking outcome data suggest it may not be an efficacious treatment strategy for AUD.
Authors
- Daniel E. Falk (ORCID: https://orcid.org/0000-0002-3753-2786)
- Thomas H. Chun (ORCID: https://orcid.org/0000-0001-7657-5554)
- Charles Scott (ORCID: https://orcid.org/0000-0003-0410-9401)
- Lara A. Ray
- Joseph P. Schacht (ORCID: https://orcid.org/0000-0003-4250-0495)
- Raye Z. Litten (ORCID: https://orcid.org/0000-0001-7497-0809)
- Joseph T. Sakai (ORCID: https://orcid.org/0000-0003-1600-6100)
- Janet H. Ransom (ORCID: https://orcid.org/0000-0002-6765-3933)
- Karen Miotto (ORCID: https://orcid.org/0000-0003-0252-6383)
- Nouf S. Alsharif
- Robert Miranda (ORCID: https://orcid.org/0000-0001-6418-6148)
- Mototsugu Ito (ORCID: https://orcid.org/0000-0003-2482-9019)
- Megan L. Ryan
Institutions
- University of California, Los Angeles (US)
- National Institute on Alcohol Abuse and Alcoholism (US)
- Fast Track Drugs and Biologics (US)
- Astellas Pharma (United States) (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Alcohol Clinical and Experimental Research
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1111/acer.15468
- Citations
- 3
- Primary Topic
- Neurotransmitter Receptor Influence on Behavior
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Astellas Pharma
- National Institute on Alcohol Abuse and Alcoholism